AHOD1331 A Randomized Phase III Study of Brentuximab Vedotin (IND#117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents

Grant

Date/time Interval

  • March 23, 2016 - March 22, 2018
  • Total Award Amount

  • 338.00
  • Direct Costs

  • 266.00
  • Sponsor Award Id

  • 9400660000
  • Contributor

  • Ana Galtarossa Xavier   Investigator  
  • Christina Bemrich-Stolz   Investigator  
  • Elizabeth Alva   Investigator  
  • Gregory Friedman M.D.   Investigator  
  • Jeffrey Lebensburger   Investigator  
  • Julie Wolfson-Stockman M.D.   Investigator  
  • Kimberly Whelan M.D.   Investigator  
  • Lee Hilliard   Investigator  
  • Matthew Kutny M.D.   Investigator  
  • Smita Bhatia M.D.   Investigator